Videos
Thursday, June 25th, 20265pm PST / 6pm MST / 7pm CST / 8pm EST
Resource
Clinical trials are research studies that involve patients (after laboratory studies have demonstrated that a new drug, treatment, or procedure works better than existing methods). The goal of a myeloma clinical trial is to improve patient care. Whether or not to participate in a clinical…
Resource
Pomalyst® (pomalidomide) is a medication used to treat adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least 2 prior therapies and whose myeloma got worse on or within 60 days of finishing their last therapy. This booklet explains how Pomalyst works, the…
Resource
In July 2025, the FDA approved the use of Lynozyfic™ (linvoseltamab-gcpt) for the treatment of adult patients with relapsed/refractory multiple myeloma (RRMM) who have received at least 4 prior lines of therapy. This booklet explains how Lynozyfic works, its dose and schedule, clinical trial…
Resource
The success of an oral treatment depends on your ability to follow the plan agreed upon by you and your doctor. To achieve the best results when you take medication by mouth, you take on the responsibility of adhering to your treatment as prescribed.
Blog post
Top Takeaways from the IMF Living Well with Myeloma Webinar: Movement for Myeloma Patients and Care Partners Learn why movement and exercise are on track to become the standard of care for myeloma patients and care partners from this March 10 IMF Living…
Resource
Myeloma is a complicated disease, but the language that describes it doesn’t have to be hard to understand. To play an active role in your own medical care, it is helpful to learn the myeloma-related terms that may be used in your discussions with your doctor, who is best able to…
Resource
There are two Ninlaro-based treatment options to be considered by patients who can benefit from an all-oral drug regimen. Ninlaro® (ixazomib) + Revlimid® (lenalidomide) + dexamethasone is a triplet (3-drug) combination known as IRd, approved by the FDA for the treatment of patients with myeloma who…
Resource
A support network is a group of people who can assist during times of need. A support network is helpful whether or not you have a single go-to care partner. Developing a support network lessens the burden on any one individual. People with a more robust support network tend to have better health…
Resource
Immunotherapy with Abecma® (idecabtagene vicleucel or “ide-cel” for short) is FDA-approved for the treatment of relapsed refractory multiple myeloma (RRMM) after 2 or more prior lines of therapy. Immunotherapy is treatment that enhances the body’s natural defenses. Chimeric antigen receptor (CAR) T…
Resource
From newly approved 4-drug frontline regimens to the expanding role of CAR T-cell therapy and bispecific antibodies, this Spring 2026 edition of Myeloma Today breaks down the clinical advances redefining what’s possible for myeloma patients today. You’ll also discover how a global…
Resource
Chimeric antigen receptor (CAR) T-Cell therapy is a cutting-edge, personalized treatment for myeloma that uses your own T-cells to target cancer. The process involves collecting and modifying your T-cells, followed by infusion and close monitoring. CAR-T is highly effective, especially for…
Resource
Based on data emerging from currently ongoing clinical trials, FDA approvals of other quadruplet regimens are anticipated in the near future.
Resource
This booklet discusses Blenrep® (belantamab mafodotin-blmf), an antibody-drug conjugate (ADC) that is a combination of a monoclonal antibody and a chemotherapy agent. Blenrep is the first and only medication in the ADC drug class that has been approved by the FDA to treat myeloma. Blenrep is unique…
Resource
Gain a basic understanding of myeloma —what the disease is, its incidence, its symptoms, and how to get support.
Resource
This booklet will familiarize you with myeloma-related bone disease (MBD) and the therapies available to prevent or treat it. Approximately 70%–80% of people with myeloma develop MBD, which can cause bones to become thinner and weaker, and can create holes in bone. The weakened…
Resource
Monoclonal gammopathy of undetermined significance (MGUS) is a non-cancerous condition associated with the possible subsequent development of myeloma. Smoldering multiple myeloma (SMM) is an asymptomatic precursor to active disease; the FDA granted its first-ever approval of a…
Resource
The IMF’s Understanding Stem Cell Transplant in Myeloma publication is intended for myeloma patients in the United States who are in discussions with their treating doctors about the possibility of having an autologous stem cell transplant (ASCT) as part of their overall treatment…
Resource
Isa-VRd is an effective “quadruplet” (4-drug) regimen that combines medicines from 4 drug classes: the monoclonal antibody Sarclisa® (isatuximab-irfc) + the proteasome inhibitor Velcade® (bortezomib) + the immunomodulatory agent Revlimid® (lenalidomide) + the steroid dexamethasone. In September…
Resource
The 2026 Winter Edition of Myeloma Today highlights IMF Chief Medical Officer Dr. Joseph Mikhael’s top 10 myeloma research abstracts from the American Society of Hematology (ASH) Annual Meeting & Exposition, including a discussion on in vivo CAR T-cell therapy and key…
Resource
Xpovio® (selinexor) is a selective inhibitor of nuclear export (SINE) compound. In 2019, Xpovio became the first medication in this drug class to receive approval from the U.S. Food and Drug Administration (FDA). Xpovio was initially used for the treatment of relapsed/refractory multiple myeloma (…
Resource
Tecvayli® (also known as teclistamab-cqyv, its generic drug name) is an immunotherapy that enhances a patient’s own immune system to attack myeloma cells. This booklet explains who can be treated with Tecvayli, how it works, how it is given, and how side effects that may occur in patients treated…
Videos
CAR T-Cell Therapy: Who Is a Candidate? | Myeloma in a MinuteCould you be a candidate for CAR T-cell therapy to treat multiple myeloma? In this quick expert explainer video, Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO discusses who may be…
Resource
Immunotherapy is treatment that engages the patient’s own immune system to attack their myeloma. Currently, there are three types of immunotherapies approved by the U.S. Food and Drug Administration (FDA) for the treatment of myeloma: monoclonal antibodies, bispecific antibodies, and chimeric…
Resource
The Fall 2025 edition of Myeloma Today celebrates the International Myeloma Foundation's remarkable 35-year journey of defying boundaries and redefining possibilities in the fight against myeloma. This milestone issue welcomes new President & CEO Heather Cooper Ortner,…
Resource
This booklet serves as an introduction to cereblon E3 ligase modulatory drugs (CELMoDs), a new class of medications currently being studied in clinical trials for the treatment of myeloma. Although CELMoDs are building on the well-established platform of immunomodulatory agents, CELMoDs are…
Page
The Role of Nutrition in Multiple MyelomaWe understand the need for a positive mindset and action plan when someone has multiple myeloma. Diet and proper nutrition contribute to these in several ways.Your body craves nutrient-rich foods during treatment. Good…
Resource
Multiple myeloma is a chronic condition that impacts the person with the diagnosis and their loved ones, especially those involved in caregiving. Care partners provide support in many ways, finding the role both gratifying and stressful. While focusing on their loved ones’ needs, care partners can…
Page
Exercise and Physical ActivityProper wellness for people living with myeloma and caregivers is partly comprised of movement. Our comprehensive myeloma wellness resources include:Mobility and safety tips…
Resource
This booklet discusses dexamethasone, a synthetic steroid that is one of the most frequently used medications in the treatment of myeloma. It can be given as either an oral tablet or as an injection, alone or in combination with other agents. Dexamethasone’s anti-inflammatory actions can stop the…
Resource
The immune system involves multiple mechanisms that work together to protect and defend the human body from external threats such as bacteria, viruses, and toxins, and from internal threats such as cancer. Myeloma is a cancer of the immune system and it is important for patients with …
Resource
Updated in April 2026, the IMF Patient Handbook offers an overview of myeloma, including its precursor conditions, diagnosis, risk stratification, and effects on the body. We hope that you will find this booklet useful. Information about treatments currently…
Resource
Carvykti® (ciltacabtagene autoleucel, or “cilta-cel” for short) is a customized immunotherapy approved by the FDA for the treatment of patients with relapsed or refractory multiple myeloma (RRMM) after at least 1 prior line of therapy. Carvykti is the first BCMA-targeted therapy approved for…
Resource
Elrexfio® (elranatamab-bcmm) is a B-cell maturation antigen (BCMA)-directed CD3 T-cell engager. In August 2023, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Elrexfio for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have…
Resource
This booklet explains the tests used to diagnose, monitor, and assess myeloma. Tests determine if and when treatment is needed. Tests identify genetic risk factors, response to treatment, risk of disease progression, and potential myeloma-related and treatment-related side effects. Each test is a…
Resource
This booklet is designed to help patients with myeloma who already have neuropathy as well as to inform patients who might be able to avoid or to mitigate the development of this problem. We hope that this booklet is also a resource for the patient’s care partners, who can help recognize…
Resource
Velcade® (bortezomib) is a proteasome inhibitor that plays a role throughout the myeloma disease course, from induction therapy for the newly diagnosed, to a possible role as part of conditioning for stem cell transplant, to consolidation/maintenance therapy, to treatment for those whose myeloma…
Resource
Care partners walk alongside their loved ones to help them live well with myeloma. Care partners are individuals who provide essential physical, emotional, and practical support to patients with myeloma.
We Thank Our Sponsors: Janssen Oncology and Pfizer
Resource
This booklet discusses Darzalex® and Darzalex Faspro® -- two different formulations of an equally effective monoclonal antibody that target the CD38 protein on the surface of myeloma cells. This targeted therapy enlists the cells of the immune system to help attack and kill myeloma cells. CD38 is…
Resource
The “triplet” (3-drug) combination of Velcade® (bortezomib) + Revlimid® (lenalidomide) + dexamethasone [VRd] is a highly effective and well-tolerated therapy for patients with newly diagnosed multiple myeloma (NDMM). Each drug has a different way of attacking myeloma, and each enhances the activity…
Resource
Overview
T-cell redirecting therapies (TCRTs), including CAR T-cell therapy and bispecific T-cell engagers (TCEs), are transforming how multiple myeloma (MM) is treated. These innovative therapies target proteins like BCMA and GPRC5D, with several options already approved worldwide and more in…
Resource
Empliciti® (elotuzumab) is the first immunostimulatory monoclonal antibody approved for the treatment of myeloma. Empliciti enlists immune system cells to attack myeloma. Before reading this booklet, it may be helpful to read another IMF publication,…
Resource
The Understanding SARCLISA® (isatuximab-irfc) booklet discusses a novel anti-CD38 monoclonal antibody that is approved for patients with relapsed and refractory myeloma. Sarclisa binds to myeloma cells to kill them directly, and also recruits other immune system cells to kill myeloma cells.
Resource
Patients with myeloma may experience fatigue caused by the disease itself or by treatment for myeloma, as well as by other medical problems or their treatment. This booklet contains a discussion of fatigue management strategies, as well as suggestions for recording and reporting fatigue to your…
Resource
Sarclisa is a novel monoclonal antibody directed against the CD38 receptor on the surface of myeloma cells. This is described as a targeted anti-myeloma therapy. Sarclisa both kills myeloma cells directly and recruits surrounding immune cells to enhance the killing process.
*updated 12/3…